# Rafael Holdings, Inc.: financial statements, quarterly

RFL · NYSE · CIK 1713863 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jul 31

Pages: [Overview](/companies/rfl.md) · [Financials](/companies/rfl/financials.md) · [Filings](/companies/rfl/filings.md) · [Insiders](/companies/rfl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rfl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-07-31) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1 d](/filings/0001213900-24-110663.md) | [0.1](/filings/0001213900-24-107637.md) | [0.1](/filings/0001213900-25-023799.md) | [0.3](/filings/0001213900-25-053273.md) | [0.2 d](/filings/0001213900-25-103549.md) | [0.1](/filings/0001213900-25-120897.md) | [0.1](/filings/0001213900-26-028348.md) | [0.4](/filings/0001213900-26-067560.md) | [(0.5) d](/filings/0001213900-25-103549.md) | [0.2](/filings/0001213900-25-120897.md) | [0.2](/filings/0001213900-26-028348.md) | [0.2](/filings/0001213900-26-067560.md) |
| Cost of revenue | $m | not reported | not reported | not reported | [0.1](/filings/0001213900-24-052918.md) | [0.1 d](/filings/0001213900-24-110663.md) | [0.0](/filings/0001213900-24-107637.md) | [0.0](/filings/0001213900-25-023799.md) | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.3 d](/filings/0001213900-24-110663.md) | [0.5](/filings/0001213900-24-107637.md) | [0.6](/filings/0001213900-25-023799.md) | [1.5](/filings/0001213900-25-053273.md) | [1.5 d](/filings/0001213900-25-103549.md) | [1.3](/filings/0001213900-25-120897.md) | [0.9](/filings/0001213900-26-028348.md) | [3.0](/filings/0001213900-26-067560.md) | [0.2](/filings/0001213900-25-103549.md) | [7.5](/filings/0001213900-25-120897.md) | [4.5](/filings/0001213900-26-028348.md) | [4.9](/filings/0001213900-26-067560.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.6) d](/filings/0001213900-24-110663.md) | [(2.5)](/filings/0001213900-24-107637.md) | [(3.1)](/filings/0001213900-25-023799.md) | [(93.2)](/filings/0001213900-25-053273.md) | [(3.8) d](/filings/0001213900-25-103549.md) | [(3.8)](/filings/0001213900-25-120897.md) | [(6.6)](/filings/0001213900-26-028348.md) | [(5.9)](/filings/0001213900-26-067560.md) | [(12.8) d](/filings/0001213900-25-103549.md) | [(10.1)](/filings/0001213900-25-120897.md) | [(6.7)](/filings/0001213900-26-028348.md) | [(6.9)](/filings/0001213900-26-067560.md) |
| Interest expense | $m | not reported | not reported | not reported | [0.1](/filings/0001213900-25-053273.md) | [0.2 d](/filings/0001213900-25-103549.md) | [0.2](/filings/0001213900-25-120897.md) | [0.2](/filings/0001213900-25-023799.md) | [0.2](/filings/0001213900-25-053273.md) | [0.2 d](/filings/0001213900-25-103549.md) | [0.2](/filings/0001213900-25-120897.md) | [0.2](/filings/0001213900-26-028348.md) | [0.0](/filings/0001213900-26-067560.md) |
| Income tax | $m | [0.0 d](/filings/0001213900-24-110663.md) | [0.0](/filings/0001213900-24-107637.md) | [0.0 d](/filings/0001213900-25-023799.md) | [(2.6)](/filings/0001213900-25-053273.md) | [(0.1) d](/filings/0001213900-25-103549.md) | [0.0](/filings/0001213900-25-120897.md) | [0.0](/filings/0001213900-26-028348.md) | [(2.4)](/filings/0001213900-26-067560.md) | [(0.2) d](/filings/0001213900-25-103549.md) | [0.0](/filings/0001213900-25-120897.md) | [0.0](/filings/0001213900-26-028348.md) | [0.0](/filings/0001213900-26-067560.md) |
| Net income | $m | [1.2 d](/filings/0001213900-24-110663.md) | [(3.6)](/filings/0001213900-24-107637.md) | [6.0](/filings/0001213900-25-023799.md) | [(32.4)](/filings/0001213900-25-053273.md) | [(4.5) d](/filings/0001213900-25-103549.md) | [(9.0)](/filings/0001213900-25-120897.md) | [(4.6)](/filings/0001213900-26-028348.md) | [(4.8)](/filings/0001213900-26-067560.md) | [(0.3)](/filings/0001213900-25-103549.md) | [(9.8)](/filings/0001213900-25-120897.md) | [(6.4)](/filings/0001213900-26-028348.md) | [(4.2)](/filings/0001213900-26-067560.md) |
| Diluted EPS | $ per share | not reported | [(0.15)](/filings/0001213900-24-107637.md) | [0.25](/filings/0001213900-25-023799.md) | [(1.36)](/filings/0001213900-25-053273.md) | not reported | [(0.37)](/filings/0001213900-25-120897.md) | [(0.19)](/filings/0001213900-26-028348.md) | [(0.19)](/filings/0001213900-26-067560.md) | not reported | [(0.19)](/filings/0001213900-25-120897.md) | [(0.13)](/filings/0001213900-26-028348.md) | [(0.08)](/filings/0001213900-26-067560.md) |
| Basic EPS | $ per share | not reported | [(0.15)](/filings/0001213900-24-107637.md) | [0.26](/filings/0001213900-25-023799.md) | [(1.36)](/filings/0001213900-25-053273.md) | not reported | [(0.37)](/filings/0001213900-25-120897.md) | [(0.19)](/filings/0001213900-26-028348.md) | [(0.19)](/filings/0001213900-26-067560.md) | not reported | [(0.19)](/filings/0001213900-25-120897.md) | [(0.13)](/filings/0001213900-26-028348.md) | [(0.08)](/filings/0001213900-26-067560.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2024-01-31) | period not labelled (2024-03-13) | Q3 FY2024 (2024-04-30) | FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | period not labelled (2024-12-05) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.1](/filings/0001213900-24-022343.md) | not reported | [7.4](/filings/0001213900-24-052918.md) | [2.7](/filings/0001213900-25-103549.md) | [8.2](/filings/0001213900-24-107637.md) | [1.0](/filings/0001213900-25-023799.md) | [48.3](/filings/0001213900-25-023799.md) | [37.9](/filings/0001213900-25-053273.md) | [52.8](/filings/0001213900-26-067560.md) | [45.5](/filings/0001213900-25-120897.md) | [37.8](/filings/0001213900-26-028348.md) | [30.5](/filings/0001213900-26-067560.md) |
| Current assets | $m | [75.1](/filings/0001213900-24-022343.md) | not reported | [73.8](/filings/0001213900-24-052918.md) | [72.5](/filings/0001213900-25-103549.md) | [70.5](/filings/0001213900-24-107637.md) | not reported | [65.8](/filings/0001213900-25-023799.md) | [42.4](/filings/0001213900-25-053273.md) | [56.7](/filings/0001213900-26-067560.md) | [48.3](/filings/0001213900-25-120897.md) | [42.4](/filings/0001213900-26-028348.md) | [34.9](/filings/0001213900-26-067560.md) |
| Total assets | $m | [106](/filings/0001213900-24-022343.md) | not reported | [102](/filings/0001213900-24-052918.md) | [96.8](/filings/0001213900-25-103549.md) | [87.8](/filings/0001213900-24-107637.md) | not reported | [83.0](/filings/0001213900-25-023799.md) | [108](/filings/0001213900-25-053273.md) | [114](/filings/0001213900-26-067560.md) | [105](/filings/0001213900-25-120897.md) | [99.3](/filings/0001213900-26-028348.md) | [92.0](/filings/0001213900-26-067560.md) |
| Current liabilities | $m | [3.3](/filings/0001213900-24-022343.md) | not reported | [7.5](/filings/0001213900-24-052918.md) | [7.5](/filings/0001213900-25-103549.md) | [7.2](/filings/0001213900-24-107637.md) | not reported | [7.1](/filings/0001213900-25-023799.md) | [11.0](/filings/0001213900-25-053273.md) | [11.6](/filings/0001213900-26-067560.md) | [12.1](/filings/0001213900-25-120897.md) | [12.4](/filings/0001213900-26-028348.md) | [11.0](/filings/0001213900-26-067560.md) |
| Total liabilities | $m | [3.9](/filings/0001213900-24-022343.md) | not reported | [11.1](/filings/0001213900-24-052918.md) | [10.6](/filings/0001213900-25-103549.md) | [10.5](/filings/0001213900-24-107637.md) | not reported | [10.5](/filings/0001213900-25-023799.md) | [23.6](/filings/0001213900-25-053273.md) | [15.7](/filings/0001213900-26-067560.md) | [16.2](/filings/0001213900-25-120897.md) | [16.1](/filings/0001213900-26-028348.md) | [11.2](/filings/0001213900-26-067560.md) |
| Current portion of debt | $m | not reported | [21.9](/filings/0001213900-26-067560.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [105](/filings/0001213900-24-022343.md) | not reported | [86.1](/filings/0001213900-24-052918.md) | [82.2](/filings/0001213900-25-103549.md) | [73.5](/filings/0001213900-24-107637.md) | not reported | [69.4](/filings/0001213900-25-023799.md) | [80.6](/filings/0001213900-25-053273.md) | [94.4](/filings/0001213900-26-067560.md) | [85.2](/filings/0001213900-25-120897.md) | [79.2](/filings/0001213900-26-028348.md) | [75.4](/filings/0001213900-26-067560.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-07-31) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.4) d](/filings/0001213900-24-110663.md) | [(2.1)](/filings/0001213900-24-107637.md) | [(2.5) d](/filings/0001213900-25-023799.md) | [(0.3) d](/filings/0001213900-25-053273.md) | [(2.9) d](/filings/0001213900-25-103549.md) | [(3.0)](/filings/0001213900-25-120897.md) | [(2.3) d](/filings/0001213900-26-028348.md) | [(3.2) d](/filings/0001213900-26-067560.md) | [(10.4) d](/filings/0001213900-25-103549.md) | [(6.8)](/filings/0001213900-25-120897.md) | [(7.5) d](/filings/0001213900-26-028348.md) | [(7.3) d](/filings/0001213900-26-067560.md) |
| Capital expenditure | $m | not reported | not reported | not reported | [0.1 d](/filings/0001213900-25-053273.md) | [0.0 d](/filings/0001213900-25-103549.md) | [0.0](/filings/0001213900-25-120897.md) | [0.0 d](/filings/0001213900-26-028348.md) | [(0.0) d](/filings/0001213900-26-067560.md) | [(0.0) d](/filings/0001213900-25-103549.md) | not reported | not reported | [0.0 d](/filings/0001213900-26-067560.md) |
| Share repurchases | $m | not reported | [0.1](/filings/0001213900-23-095748.md) | [0.1 d](/filings/0001213900-24-022343.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-10-31) | Q2 FY2023 (2023-01-31) | Q3 FY2023 (2023-04-30) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.0](/filings/0001213900-23-095748.md) | [23.2](/filings/0001213900-24-022343.md) | [23.4](/filings/0001213900-24-052918.md) | [23.6](/filings/0001213900-24-107637.md) | [24.4](/filings/0001213900-25-023799.md) | [23.8](/filings/0001213900-25-053273.md) | [24.1](/filings/0001213900-25-120897.md) | [24.2](/filings/0001213900-26-028348.md) | [25.2](/filings/0001213900-26-067560.md) | [51.2](/filings/0001213900-25-120897.md) | [51.2](/filings/0001213900-26-028348.md) | [51.2](/filings/0001213900-26-067560.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100 at 2018-03-12, from the cover of the [10-Q filed 2018-03-12](/filings/0001213900-18-002820.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.